Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · Bayer Taiwan
№ 96 · The Bayer Taiwan dossier

Bayer Taiwan

拜耳台灣
Parent: Bayer AG (Xetra: BAYN; OTC: BAYRY)
Readiness
60
Greenfield
Capped at 95. High confidence — AOR sourced within 0y · high-confidence research.
Workspace · saved locally in your browser
Pipeline status
Your notes · Bayer Taiwan
Saves on blur. Stored in your browser only — not synced.

Three-division MNC: Pharmaceuticals (Rx — Eylea, Xarelto, Nubeqa), Consumer Health (OTC + wellness — Aspirin, Bepanthen, Berocca, Aleve, One A Day, Redoxon, Iberogast), Crop Science (B2B agro). Consumer Health is the meaningful TW brand-marketing surface. As of Oct 2025, Bayer Consumer Health consolidated globally with IPG — WPP LOST this $720M account. AI-led integrated model (IPG Interact).

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 60
score breakdown
Intel depth (7 wedges · M&A, recent, transformation)research_depth+60
Total · capped 9560
30-day signal trajectory
0 signals · spend N/A
Intel wedges
7/8
7 of 8 wedges corroborated. Research confidence: high — Oct 2025 IPG global Consumer Health consolidation publicly documented across Bayer press, BusinessWire, AdWeek, FiercePharma, MediaPost, AdAge..
Open playbook →
Recommended posture
Watch closely.
Bayer Pharmaceuticals (Rx) is a SEPARATE scope from Consumer Health — IPG win covers only Consumer Health. WPP can still pitch Rx TW (Eylea retinal, Xarelto anticoagulant, Nubeqa oncology)